Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth

Cancer Biology and Therapy

Volumn 13, Issue 12, 2012, Pages 1185-1194

  Van Den Heuvel, A Pieter J ^a   Jing, Junping ^a   Wooster, Richard F ^a   Bachman, Kurtis E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

BPTES; Cancer; Glutaminase; Glutamine; Glutaminolysis; NSCLC

Indexed keywords

GLUTAMINASE; GLUTAMINASE C; GLUTAMINE; KIDNEY GLUTAMINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; DOWNSTREAM PROCESSING; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; METABOLITE; ONCOGENE; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; GLUTAMINASE; GLUTAMINE; GLYCOLYSIS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN ISOFORMS;

EID: 84867130104     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21348     Document Type: Article

References (30)

1. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10:267-77; PMID:20300106; http://dx.doi.org/10.1038/nrc2817.
2. Fischer CP, Bode BP, Souba WW. Adaptive alterations in cellular metabolism with malignant transformation. Ann Surg 1998; 227:627-34, discussion 634-6; PMID:9605654; http://dx.doi.org/10.1097/00000658-199805000-00003.
3. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, et al. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 2011; 117:2926-38; PMID:21692052; http://dx.doi.org/10.1002/cncr.25868.
4. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29:313-24; PMID:19881548; http://dx.doi.org/10.1038/onc.2009.358.
5. Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle 2010; 9:3921-32; PMID:20935507; http://dx.doi.org/10.4161/cc.9.19.13139.
6. Matés JM, Pérez-Gómez C, Núñez de Castro I, Asenjo M, Márquez J. Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. Int J Biochem Cell Biol 2002; 34:439-58; PMID:11906817; http://dx.doi.org/10.1016/ S1357-2725(01)00143-1.
7. Backos DS, Franklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol.
8. Elgadi KM, Meguid RA, Qian M, Souba WW, Abcouwer SF. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1999; 1:51-62; PMID:11015561.
9. Perera SY, Chen TC, Curthoys NP. Biosynthesis and processing of renal mitochondrial glutaminase in cultured proximal tubular epithelial cells and in isolated mitochondria. J Biol Chem 1990; 265:17764-70; PMID:2211660.
10. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458:762-5; PMID:19219026; http://dx.doi.org/10.1038/nature07823.
11. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008; 105:18782-7; PMID:19033189; http://dx.doi.org/10.1073/pnas.0810199105.
12. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Krasmediated tumorigenicity. Proc Natl Acad Sci U S A 2010; 107:8788-93; PMID:20421486; http://dx.doi.org/10.1073/pnas.1003428107.
13. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18:207-19; PMID:20832749; http://dx.doi.org/10.1016/j.ccr. 2010.08.009.
14. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70:8981-7; PMID:21045145; http://dx.doi.org/10. 1158/0008-5472.CAN-10-1666.
15. Lobo C, Ruiz-Bellido MA, Aledo JC, Márquez J, Núñez De Castro I, Alonso FJ. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J 2000; 348:257-61; PMID:10816417; http://dx.doi.org/10.1042/0264-6021:3480257.
16. Lora J, Alonso FJ, Segura JA, Lobo C, Márquez J, Matés JM. Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells. Eur J Biochem 2004; 271:4298-306; PMID:15511236; http://dx.doi.org/10.1111/j.1432-1033.2004.04370.x.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49; PMID:19474385; http://dx.doi.org/10.3322/ caac.20006.
18. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, et al. Molecular target class is predictive of in vitro response profile. Cancer Res 2010; 70:3677-86; PMID:20406975; http://dx.doi.org/10.1158/0008-5472.CAN-09- 3788.
19. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, et al. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer 2011; 129:355-64; PMID:20878980; http://dx.doi.org/10.1002/ijc.25704.
20. Pinkus LM. Glutamine binding sites. Methods Enzymol 1977; 46:414-27; PMID:909432; http://dx.doi.org/10.1016/S0076-6879(77)46049-X.
21. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES). Biochem J 2007; 406:407-14; PMID:17581113; http://dx.doi.org/10.1042/BJ20070039.
22. Roberg BA, Torgner IA, Kvamme E. Kinetics of a novel isoform of phosphate activated glutaminase (PAG) in SH-SY5Y neuroblastoma cells. Neurochem Res 2010; 35:875-80; PMID:19894115; http://dx.doi.org/10.1007/s11064-009-0077-7.
23. Szeliga M, Obara-Michlewska M. Glutamine in neoplastic cells: focus on the expression and roles of glutaminases. Neurochem Int 2009; 55:71-5; PMID:19428809; http://dx.doi.org/10.1016/j.neuint.2009.01.008.
24. Szeliga M, Matyja E, Obara M, Grajkowska W, Czernicki T, Albrecht J. Relative expression of mRNAS coding for glutaminase isoforms in CNS tissues and CNS tumors. Neurochem Res 2008; 33:808-13; PMID:17940881; http://dx.doi.org/10. 1007/s11064-007-9507-6.
25. Porter LD, Ibrahim H, Taylor L, Curthoys NP. Complexity and species variation of the kidney-type glutaminase gene. Physiol Genomics 2002; 9:157-66; PMID:12045296.
26. Cassago A, Ferreira AP, Ferreira IM, Fornezari C, Gomes ER, Greene KS, et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A 2012; 109:1092-7; PMID:22228304; http://dx.doi.org/10.1073/pnas. 1112495109.
27. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43:969-80; PMID:20156581; http://dx.doi.org/10.1016/j.biocel.2010.02.005.
28. Yoshioka K, Takehara H, Okada A, Komi N. Glutamine antagonist with diet deficient in glutamine and aspartate reduce tumor growth. Tokushima J Exp Med 1992; 39:69-76; PMID:1412455.
29. Unterluggauer H, Mazurek S, Lener B, Hütter E, Eigenbrodt E, Zwerschke W, et al. Premature senescence of human endothelial cells induced by inhibition of glutaminase. Biogerontology 2008; 9:247-59; PMID:18317946; http://dx.doi.org/10.1007/s10522-008-9134-x.
30. Wu F, Lukinius A, Bergström M, Eriksson B, Watanabe Y, Långström B. A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria. Eur J Cancer 1999; 35:1155-61; PMID:10533463; http://dx.doi.org/10.1016/S0959-8049(99)00099-4.